Roche executive says Alzheimer’s drug price will be competitive

FILE PHOTO: A logo of Swiss pharmaceutical company Roche in Rotkreuz, Switzerland, April 12, 2012.REUTERS/Michael Buholzer
November 10, 2021
By Deena Beasley
(Reuters) – Roche Holding AG, still months away from seeking regulatory approval of its experimental Alzheimer’s drug, is already taking aim at rival Biogen Inc’s Aduhelm, saying that its medication would be priced competitively.

Read the source article at One America News Network
2021-11-10 12:58:30